Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument
MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq:AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it’s 1,000th instrument, a significant milestone for the company and the largest installed base in the spatial biology industry. Akoya platforms have gained widespread adoption in discovery and translational research laboratories around the world, setting the stage for clinical use. Akoya’s industry leading instrument portfolio includes the PhenoCycler®, PhenoImager® Fusion and the PhenoImager HT.
Related news for (AKYA)
- Today’s Top Performers: MoBot’s Market Review 05/21/25 08:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/21/25 07:00 AM
- Akoya Biosciences Reports First Quarter 2025 Financial Results
- Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
- Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025